Rachel Rich

Agricultural and Biological SciencesEconomics, Econometrics and FinanceArts and HumanitiesMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “Evaluation of elexacaftor–tezacaftor–ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial”.

Evaluation of elexacaftor–tezacaftor–ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial

The Lancet Respiratory Medicine(2024)10.1016/s2213-2600(24)00205-4

N/A

1.1DataRank · unranked

28 citations

Rachel W. Linnemann, Rachel Rich, Ashleigh Streby, Brian Buehler, Eric Hunter +14 more